Unjha Formulations Limited (BOM:531762)
32.17
+1.53 (4.99%)
At close: Sep 7, 2026
Unjha Formulations Revenue
Unjha Formulations had revenue of 33.08M INR in the quarter ending June 30, 2026, a decrease of -8.98%. This brings the company's revenue in the last twelve months to 152.79M, up 12.27% year-over-year. In the fiscal year ending March 31, 2026, Unjha Formulations had annual revenue of 155.85M with 11.89% growth.
Revenue (ttm)
152.79M
Revenue Growth
+12.27%
P/S Ratio
0.90
Revenue / Employee
10.19M
Employees
15
Market Cap
137.28M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 155.85M | 16.56M | 11.89% |
| Mar 31, 2025 | 139.30M | -45.66M | -24.69% |
| Mar 31, 2024 | 184.96M | 53.42M | 40.61% |
| Mar 31, 2023 | 131.54M | -10.24M | -7.22% |
| Mar 31, 2022 | 141.77M | 42.16M | 42.32% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Add-Shop E-Retail | 1.71B |
| Walpar Nutritions | 757.46M |
| Beryl Drugs | 213.23M |
| Zenith Healthcare | 108.46M |
| Hamps Bio | 84.75M |
| Norris Medicines | 76.00M |
| Desh Rakshak Aushdhalaya | 66.33M |
| Colinz Laboratories | 58.11M |